Fig. 4: Potential therapeutic targets in Treg mediated muscular dystrophy.
From: Regulatory T cells in skeletal muscle repair and regeneration: recent insights
Tregs delay the progression of DMD by releasing IL-10. In addition, Tregs suppress the inflammatory response by limiting the release of IFN-γ from effector T cells and releasing IL-5 which promotes the conversion of M1 macrophages to M2 macrophages. Tcra and Tcrb recombinant gene therapy and blockade of the ATP/P2X signalling pathway have potential in DMD treatment by regulating Tregs and delaying muscular dystrophy progression. DMD, Duchenne muscular dystrophy.
